anti-PTPRZ1 peptide nanovesicle

The anti-PTPRZ1 peptide nanovesicle is a targeted drug delivery platform currently in preclinical development for the treatment of glioblastoma multiforme (GBM). It consists of a nanovesicle—typically a liposome or similar lipid-based nanoparticle—functionalized with a specific peptide ligand (such as PTP-TP) that high-affinity binds to Protein Tyrosine Phosphatase Receptor Type Z1 (PTPRZ1). PTPRZ1 is a cell surface receptor that is highly overexpressed in glioma cells and glioma stem cells but has limited expression in normal adult brain tissue, making it an ideal target for precision oncology. By leveraging the PTPRZ1-targeting peptide, these nanovesicles can effectively cross the blood-brain barrier (BBB) and selectively accumulate within the tumor microenvironment. Once at the target site, the nanovesicles deliver encapsulated therapeutic payloads, such as small molecule chemotherapeutics or nucleic acids, to inhibit tumor growth and recurrence while minimizing systemic toxicity.

Other names

PTPRZ1-targeting peptide-functionalized nanovesiclePTPRZ-1-targeting peptide-functionalized nanovesiclePTPRZ 1-targeting peptide-functionalized nanovesiclePTPRZ1-targeted nanovesiclePTPRZ-1-targeted nanovesiclePTPRZ 1-targeted nanovesiclePTP-TP-NV